References
- WHO. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern. 2021. Available from: https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sarscov-2-variant-of-concern.
- Araf Y, Akter F, Tang Y-d, et al. Omicron variant of SARS-CoV-2: Genomics, transmissibility, and responses to current COVID-19 vaccines. J Med Virol. 2022;1–8.
- GISAID. 2021. Available from: https://www.gisaid.org/hcov19-variants/.
- Zhang L, Li Q, Liang Z, et al. The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron. Emerg Microbes Infect. 2022;11:1–5.
- Bar-On YM, Goldberg Y, Mandel M, et al. Protection of BNT162b2 vaccine booster against Covid-19 in Israel. N. Engl. J. Med. 2021;385:1393–1400.
- Nie J, Li Q, Wu J, et al. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerg Microbes Infect. 2020;9:680–686.
- Pulliam JRC, van Schalkwyk C, Govender N, et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa. 2021:2021.11.11.21266068. [cited 2021 Dec 4]. Available from: https://www.medrxiv.org/content/10.1101/2021.11.11.21266068v2.
- Wilhelm A, Widera M, Grikscheit K, et al. Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera and monoclonal antibodies. medRxiv. medRxiv. 2021:2021.12.07.21267432.
- Pfizer and BioNTech Provide Update on Omicron Variant [cited 2021 Dec 8]. Available from: https://www.pfizer.com/news/pressrelease/press-release-detail/pfizer-and-biontech-provide-updateomicron-varian.